Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
H Döhner, EH Estey, S Amadori… - Blood, The Journal …, 2010 - ashpublications.org
In 2003, an international working group last reported on recommendations for diagnosis,
response assessment, and treatment outcomes in acute myeloid leukemia (AML). Since that …
response assessment, and treatment outcomes in acute myeloid leukemia (AML). Since that …
How I treat refractory and early relapsed acute myeloid leukemia
F Thol, RF Schlenk, M Heuser… - Blood, The Journal of …, 2015 - ashpublications.org
Abstract Between 10% and 40% of newly diagnosed patients with acute myeloid leukemia
(AML) do not achieve complete remission with intensive induction therapy and are therefore …
(AML) do not achieve complete remission with intensive induction therapy and are therefore …
Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD
RF Schlenk, D Weber, W Fiedler… - Blood, The Journal …, 2019 - ashpublications.org
Patients with acute myeloid leukemia (AML) and a FLT3 internal tandem duplication (ITD)
have poor outcomes to current treatment. A phase 2 hypothesis-generating trial was …
have poor outcomes to current treatment. A phase 2 hypothesis-generating trial was …
Differential impact of allelic ratio and insertion site in FLT3-ITD–positive AML with respect to allogeneic transplantation
RF Schlenk, S Kayser, L Bullinger… - Blood, The Journal …, 2014 - ashpublications.org
The objective was to evaluate the prognostic and predictive impact of allelic ratio and
insertion site (IS) of internal tandem duplications (ITDs), as well as concurrent gene …
insertion site (IS) of internal tandem duplications (ITDs), as well as concurrent gene …
TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome
FG Rücker, RF Schlenk, L Bullinger… - Blood, The Journal …, 2012 - ashpublications.org
To assess the frequency of TP53 alterations and their correlation with other genetic changes
and outcome in acute myeloid leukemia with complex karyotype (CK-AML), we performed …
and outcome in acute myeloid leukemia with complex karyotype (CK-AML), we performed …
Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials
Context The optimal treatment of acute myeloid leukemia (AML) in first complete remission
(CR1) is uncertain. Current consensus, based on cytogenetic risk, recommends …
(CR1) is uncertain. Current consensus, based on cytogenetic risk, recommends …
The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML
S Kayser, K Doehner, J Krauter… - Blood, The Journal …, 2011 - ashpublications.org
To study the characteristics and clinical impact of therapy-related acute myeloid leukemia (t-
AML). 200 patients (7.0%) had t-AML and 2653 de novo AML (93%). Patients with t-AML …
AML). 200 patients (7.0%) had t-AML and 2653 de novo AML (93%). Patients with t-AML …
Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 …
Purpose We investigated the effect on outcome of measurable or minimal residual disease
(MRD) status after each induction course to evaluate the extent of its predictive value for …
(MRD) status after each induction course to evaluate the extent of its predictive value for …
Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene …
K Döhner, RF Schlenk, M Habdank, C Scholl… - Blood, 2005 - ashpublications.org
To assess the prognostic relevance of mutations in the NPM1 gene encoding a
nucleocytoplasmic shuttle protein in younger adults with acute myeloid leukemia (AML) and …
nucleocytoplasmic shuttle protein in younger adults with acute myeloid leukemia (AML) and …
Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further …
E Taskesen, L Bullinger, A Corbacioglu… - Blood, The Journal …, 2011 - ashpublications.org
We evaluated concurrent gene mutations, clinical outcome, and gene expression signatures
of CCAAT/enhancer binding protein alpha (CEBPA) double mutations (CEBPA dm) versus …
of CCAAT/enhancer binding protein alpha (CEBPA) double mutations (CEBPA dm) versus …